Stockscreener 앱 받기
0.7251
2.87%
-0.0214
시간 외 거래:
.73
0.0049
+0.68%
전일 마감가:
$0.7465
열려 있는:
$0.73
하루 거래량:
1.35M
Relative Volume:
0.34
시가총액:
$71.05M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-7.41%
1개월 성능:
-10.72%
6개월 성능:
-86.03%
1년 성능:
-80.61%
1일 변동 폭
$0.7171
$0.7451
1주일 범위
$0.7106
$0.80
52주 변동 폭
$0.64
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.7251 | 73.15M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
How aTyr Pharma Inc. stock benefits from tech adoptionMarket Growth Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Will aTyr Pharma Inc. stock outperform growth indexesTrade Entry Report & Free Technical Confirmation Trade Alerts - ulpravda.ru
Can aTyr Pharma Inc. (471A) stock sustain breakout momentumDay Trade & Safe Capital Allocation Plans - ulpravda.ru
Aug EndMonth: Will aTyr Pharma Inc. stock split attract more investorsJuly 2025 WrapUp & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
How strong is aTyr Pharma Inc. stock revenue growthPortfolio Return Report & Low Risk Investment Opportunities - ulpravda.ru
aTyr Pharma, Inc. (ATYR) Stock Analysis: Unveiling a 483% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Will aTyr Pharma Inc. stock attract ESG investorsStock Watchlist Updates & Exceptional Trading Strategies - ulpravda.ru
aTyr Pharma, Inc.Common Stock (NQ: ATYR - FinancialContent
Will aTyr Pharma Inc. (471A) stock beat Nasdaq index returns2026 world cup usa national team quarterfinals playmakers high defensive line expert forecast preview - Улправда
Class Action Lawsuit Filed: aTyr Pharma, Inc. (ATYR)Join by December 8, 2025Contact Levi & Korsinsky - The National Law Review
Is aTyr Pharma Inc. stock affected by interest rate hikesJuly 2025 Snapshot & Free Safe Entry Trade Signal Reports - Улправда
How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Buyback Activity & Fast Momentum Stock Entry Tips - Улправда
ATyr Pharma, Inc.(NasdaqCM:ATYR) dropped from S&P Biotechnology Select Industry Index - marketscreener.com
Will aTyr Pharma Inc. stock remain a Wall Street favorite2025 Top Gainers & Technical Confirmation Alerts - Улправда
Winners Losers: Will aTyr Pharma Inc. stock remain a Wall Street favoriteWeekly Investment Recap & Accurate Entry/Exit Alerts - Улправда
Why analysts raise outlook for aTyr Pharma Inc. (471A) stockExit Point & AI Forecast for Swing Trade Picks - DonanımHaber
Aug Fed Impact: How aTyr Pharma Inc. stock reacts to inflationary pressures2025 Growth vs Value & Daily Market Momentum Tracking - Улправда
Johnson Fistel Investigates Claims on Behalf of aTyr Pharma, Inc. (ATYR) Shareholders - marketscreener.com
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
aTyr Pharma, Inc. (NASDAQ:ATYR) Given Consensus Rating of “Hold” by Brokerages - Defense World
Healthy Upside Potential: Atyr Pharma Inc (ATYR) - Setenews
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit - Morningstar
ATYR Deadline: ATYR Investors with Losses Have Opportunity to Le - GuruFocus
Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - Louisiana First News
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) - GlobeNewswire
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - galvnews.com
ATYR DEADLINE ALERT: Hagens Berman Alerts aTyr Pharma - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc - GuruFocus
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATYR LAWSUIT ALERT: The Gross Law Firm Notifies aTyr Pharma, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - marketscreener.com
ATyr Pharma, Inc. Investigated for Securities Fraud ViolationsContact the DJS Law Group to Discuss Your RightsATYR - marketscreener.com
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securi - GuruFocus
ATYR DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - TMX Newsfile
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire
ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - GlobeNewswire Inc.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Newsfile
מועד אחרון לתביעה נגד ATYR: רוזן, משרד עורכי דין מוערך בעולם, מעודדים את משקיעי ATyr Pharma, Inc עם הפסדים של מעל מאה אלף דולר, להשיג ייעוץ לפני המועד החשוב של 8 בדצמבר בתביעה ייצוגית בניירות ערך - GlobeNewswire Inc.
ATYR DEADLINE MONDAY: ROSEN, A GLOBALLY RESPECTED LAW FIRM, - GlobeNewswire
aTyr Pharma Receives Nasdaq Deficiency Notice - TipRanks
Investors who lost money on aTyr Pharma, Inc.(ATYR) should contact Levi & Korsinsky about pending Class ActionATYR - cnhinews.com
ATyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - marketscreener.com
aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - Prime Publishers, Inc.
SueWallSt Podcast Series Launches With Focus on aTyr Pharma, Inc. (ATYR) Fraud Allegations - ACCESS Newswire
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Inves - GuruFocus
ATYR 3-DAY DEADLINE ALERT: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure - marketscreener.com
Holzer & Holzer, LLC Reminds Investors of Upcoming December - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Deadline Soon: aTyr Pharma Inc. (ATYR) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit - The AI Journal
Atyr Pharma Inc (ATYR) 재무 분석
Atyr Pharma Inc (ATYR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.80%
4.56%
자본화:
|
볼륨(24시간):